Dear Friends,

As the autumn turns to winter and falling leaves give way to the possibility of falling snow, I find myself reflecting on the dramatic changes we have all experienced this past year — and the impact of pulling together as a community. Our world may look different, but there remain many constants that bring me hope and confidence as we look ahead.

Penn Medicine’s Ovarian Cancer Research Center (OCRC) is driven by and for people: people who study, treat, and support those affected by ovarian cancer. Teamwork is the critical ingredient to our success, and a signature trait of the OCRC. Our unparalleled team has enabled our science-driven, patient-focused efforts.

We couldn’t do it without you, our generous supporters. Thank you for being part of our team.

Wishing you a safe, reflective season,

Ronny Drapkin, MD, PhD
Director, Penn Medicine’s Ovarian Cancer Research Center
Create a Lasting Impact

Planned giving provides an opportunity for donors to create a legacy that will have a lasting impact on the future of gynecologic cancer research, and the potential to benefit their own estate planning.

The programs of the Ovarian Cancer Research Center depend upon your support. There are many planned giving options including: directing a **Qualified Charitable Distribution** from your retirement account or naming Penn Medicine’s OCRC as a **beneficiary** in your retirement plan or insurance policy; to specifying gifts of real estate, stock, and other **assets** our supporters might not suspect could be designated to support the OCRC.

Visit [PennMedicine.org/PlannedGiving](http://PennMedicine.org/PlannedGiving) or call (215) 898-9486.

---

**Ronny Drapkin, MD, Discusses Advances in Ovarian Cancer Treatment Research**

Listen as Dr. Drapkin discusses how the Ovarian Cancer Translational Center of Excellence has expanded Penn's tissue collection and infrastructure, and the ways in which his team is approaching a genetic, molecular and physiological understanding of the development of ovarian cancer.
October 19th marked the second Helene Ross Bogutz Symposium on Early Detection Strategies for Ovarian Cancer, this year in special partnership with the Mikuta Lectureship. More than 150 people tuned in to hear cutting-edge research from investigators across the country, including Dr. Andrew Godwin from the University of Kansas and Surbhi Sarna, an inspiring women's health entrepreneur. 

It’s not too late to hear the discussion. From advances in exosome biology and microRNAs to liquid biopsies and fascinating bioengineering approaches, there is much promise on the horizon.

Watch Here

A Conversation with Ashley F. Haggerty, MD, MSCE

Get to know one of our dynamic faculty members in this Q & A. Explore Dr. Haggerty’s motivation for improving patient outcomes, including her current work on the phase II rucaparib trial that is examining the novel, targeted PARP inhibitor after chemotherapy in high-risk endometrial cancers.